Maky Zanganeh: From Revolutionary Tehran to Biotech Trailblazer

Growing up in Tehran during the upheaval of the 1979 Islamic Revolution, Maky Zanganeh experienced firsthand the turmoil that shaped her early life.She recalls a harrowing night when armed forces deployed tear gas and gunfire near her home while she and her sisters were left alone. Despite such chaos, daily routines persisted: “We woke up at 7 a.m. and went to school as if nothing had happened,” she remembers with composed determination.

Crossing Borders: Education and Early Career Shifts

In 1984, seeking stability amid political unrest, Zanganeh’s architect parents moved the family to Germany. Settling in Oldenburg near Bremen with relatives, she immersed herself in a disciplined academic environment grounded in strong cultural values prioritizing education and well-being.While her older sisters pursued medical degrees in Strasbourg, France, Maky chose dentistry at Louis Pasteur University (now University of Strasbourg), completing her studies by 1995.

yet dentistry soon felt limiting for her ambitions.Drawn by advances in medical technology, she joined Computer Motion-a pioneering U.S.-based firm developing robotic surgical systems-at their Strasbourg branch in 1997. Encouraged by her father to blend technical expertise with business savvy, she earned an MBA from Schiller International University part-time by 1998.

Pioneering Robotic Surgery Across Continents

By age 28, Zanganeh was overseeing Computer Motion’s operations throughout europe and the Middle East-introducing surgeons from Dubai to Cairo to innovative robotic-assisted procedures-and forging a close working relationship with CEO Bob Duggan. Their complementary strengths combined Duggan’s visionary entrepreneurship with Zanganeh’s precise operational leadership.

the Leap into Cancer Therapeutics

Following Duggan’s sale of Computer Motion in 2003, they sought new challenges together. Their attention turned toward Pharmacyclics-a struggling biotech focused on cancer drugs-which resonated personally after Duggan lost his son to brain cancer. Taking important financial risks (Zanganeh even secured personal loans), they assumed leadership roles that would transform Pharmacyclics’ trajectory.

The Breakthrough Impact of Imbruvica on Leukemia Care

Their bold investment culminated in Imbruvica-a revolutionary therapy for chronic lymphocytic leukemia offering patients fewer adverse effects than conventional chemotherapy regimens. FDA approval arrived in 2013; two years later AbbVie acquired Pharmacyclics for $21 billion. With an initial stake around $1 million invested jointly, Zanganeh realized pre-tax earnings nearing $225 million as this game-changing drug reshaped oncology treatment worldwide.

A Personal Health Battle Inspires Deeper Commitment

Maky balanced this rapid ascent while raising her son shaun largely independently; during extensive travels for work he was primarily cared for by his grandmother until age five (Duggan has acknowledged paternity). In late 2019 during a trip visiting family where her father underwent cancer surgery,Zanganeh discovered a Stage II breast cancer diagnosis herself.

Treatment coincided painfully with COVID-19 lockdowns; chemotherapy severely affected both heart and lung function requiring hospitalization amid intense bone pain and nausea episodes testing physical endurance profoundly: “I was very ill… constantly fearing metastasis.” This intimate struggle deepened empathy toward patients confronting similar battles globally.

Navigating Summit Therapeutics Toward Global Biotech Leadership

In April 2020 Bob Duggan acquired majority control over Summit therapeutics-a Miami-based biotech than generating under $1 million annually but facing heavy losses-and became CEO shortly before appointing Maky COO seven months later once she recovered sufficiently from treatment.

An initial antibiotic project faltered but quick strategic pivots led them on an international search culminating mid-2022 when former colleague Fong Clow recommended exploring Akeso Pharmaceuticals’ promising lung cancer candidate ivonescimab-already advancing thru Phase III trials-in China.

A Strategic Bet Challenging Industry Conventions

• The December 2022 licensing agreement involved $500 million upfront plus potential milestones totaling $4.5 billion contingent upon regulatory approvals;
• This deal required personal loans from both CEOs given Summit’s modest cash reserves (~$120 million) versus market capitalization (~$200 million) at signing;
• The partnership thrived partly due to shared entrepreneurial culture between Akeso founder Michelle Xia-who trained extensively across Europe & U.S.-and Summit leadership;
• Ivonescimab employs dual mechanisms attacking tumors via immune system activation alongside cutting off blood supply;
• Pivotal trials conducted mainly within China showed median progression-free survival nearly twice that of Keytruda-the global leader expected to generate close to $30 billion sales this year just from lung cancers;
• An FDA submission is anticipated before year-end following ongoing multiple Phase III studies worldwide targeting various lung cancer subtypes where annual mortality exceeds125K Americans per National Cancer Institute data;
• A recent trial miss on overall survival endpoint caused stock volatility but analysts emphasize positive disease progression results suggest durable benefits especially among select patient groups;
• Zanganeh stresses urgency driven not onyl professionally but personally given survivor viewpoint urging rapid decision-making focused squarely on patient outcomes rather than bureaucratic delays or conventional constraints.

Synthesizing Visionary Leadership With Scientific Innovation

“Maky stands out as one of biotech’s most underrated executives,” notes industry veteran Ken Clark,
a legal advisor who has served numerous boards including Summit Therapeutics.
Her ability alongside Duggan-to challenge orthodoxies swiftly yet thoughtfully-is central
to their remarkable rise despite lacking customary scientific backgrounds.”

A Leading Figure Among America’s Self-Made Women Billionaires

Zanganeh currently ranks No. 23 among America’s Richest self-Made Women-the exclusive group featuring only five female healthcare billionaires nationwide-as recognized through decades-long innovation combined with strategic risk-taking spanning multiple continents.

A Legacy Defined By Resilience And Relentless Impact

• Cultural fluency: Proficient across four languages (Farsi,German,French,and English), adeptly navigating diverse global environments;
• Diverse expertise: From clinical dentistry through advanced medical robotics into high-stakes pharmaceutical development;
• Keen investor: navigated complex deals securing unprecedented revenue-sharing arrangements benefiting smaller firms like Pharmacyclics;
• Cancer survivor: brings firsthand insight fueling commitment towards accelerating life-saving therapies worldwide;
• Pioneering mindset: taps overlooked opportunities such as Chinese biopharma collaborations defying prevailing industry skepticism;